Acumen Pharmaceuticals Stock Forum

$Acumen Pharmaceuticals (ABOS.US)$
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease
Acumen Pharmaceuticals presented data on using pTau217 assay as an efficient screening tool for their Phase 2 ALTITUDE-AD clinical trial of sabirnetug for early Alzheimer's disease. The assay, with a threshold of ≥0.15 pg/mL, effectively identifie...

$Rimini Street (RMNI.US)$ $Acumen Pharmaceuticals (ABOS.US)$ $Molina Healthcare (MOH.US)$ $BioVie (BIVI.US)$ $Allakos (ALLK.US)$ $CNS Pharmaceuticals (CNSP.US)$ $GraniteShares 2x Long TSLA Daily ETF (TSLR.US)$ $Direxion Daily TSLA Bull 2X Shares (TSLL.US)$ $T-REX 2X LONG TESLA DAILY TARGET ETF (TSLT.US)$ $Twin Vee PowerCats (VEEE.US)$ $EpicQuest Education (EEIQ.US)$ $Mobile-health Network Solutions (MNDR.US)$
📊⚡️📊

$Acumen Pharmaceuticals (ABOS.US)$
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
Acumen Pharmaceuticals (NASDAQ: ABOS) presented new findings from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer's Association International Conference 2024.
The research focuses on patient experiences, biomarker data, and a new ultra-sensitive assay for measuring s...

$Acumen Pharmaceuticals (ABOS.US)$
Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
Acumen Pharmaceuticals (NASDAQ: ABOS) announced it will present patient experience and biomarker data from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer's Association International Conference (AAIC) 2024. The conference will be held in Philadelphia and online ...

$Acumen Pharmaceuticals (ABOS.US)$
NEWS
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
Sabirnetug demonstrated a favorable safety profile with low incidence of ARIA-E in early AD participants.
Target engagement with AβOs in cerebrospinal fluid increased in a dose-dependent manner, suggesting active removal of target from the brain.
Sabirnetug treatment led to changes in CSF and plasma bio...

$Acumen Pharmaceuticals (ABOS.US)$ Acumen Pharmaceuticals Collaborates With Lonza Covering The Manufacture Of Sabirnetug (ACU193) For Alzheimer's Disease, For Clinical Development And Commercialization, If Approved

$Acumen Pharmaceuticals (ABOS.US)$
slowly moving up

$Acumen Pharmaceuticals (ABOS.US)$ announced that it has entered into a senior secured loan and security agreement  with K2 HealthVentures, a healthcare-focused specialty finance company.

$Acumen Pharmaceuticals (ABOS.US)$ Just off ATL ( you know how i likes me some bottom bouncers, hehehe ) Earnings out Monday 11/13/23 BMO!  But mainly for the following! Phase 1 data on ACU193/INTERCEPT-AD was very promising! The Recent collaboration & License agreement with HALOZYME Could make this Alzheimer’s treatment a game changer for patients by allowing the delivery of the drug Subcutaneously instead of IV? Which would be much more convenient and less inva...

$Acumen Pharmaceuticals (ABOS.US)$ Acumen Pharmaceuticals, Inc. And Halozyme Enter Global Collaboration And License Agreement To Develop Subcutaneous Formulation Of ACU193 With ENHANZE Technology